Indications |
Oral Acute bronchospasm Adult: 80 mcg bid. Child: >6 mth: 4 mcg/kg/day, given in 2-3 divided doses. Oral Reversible airways obstruction Adult: 80 mcg bid. Child: >6 mth: 4 mcg/kg/day, given in 2-3 divided doses. Inhalation Acute bronchospasm Adult: As inhalational capsule: 12 mcg bid; up to 24 mcg bid in severe cases. As dry powder inhaler: 6 or 12 mcg 1-2 times daily, up to 24 mcg bid in severe cases. As metered doses from aerosol inhaler (per inhalation into mouthpiece contains 12 mcg): 1-2 inhalations bid. As nebuliser: 20 mcg bid. Child: As inhalational capsule: ≥5 yr: 12 mcg bid. As dry powder inhaler: ≥6 yr: 6 or 12 mcg 1-2 times daily; up to 48 mcg/day; max: 12 mcg/dose. Inhalation Reversible airways obstruction Adult: As inhalational capsule: 12 mcg bid; up to 24 mcg bid in severe cases. As dry powder inhaler: 6 or 12 mcg 1-2 times daily, up to 24 mcg bid in severe cases. As metered doses from aerosol inhaler (per inhalation into mouthpiece contains 12 mcg): 1-2 inhalations bid. As nebuliser: 20 mcg bid. Child: As inhalational capsule: ≥5 yr: 12 mcg bid. As dry powder inhaler: ≥6 yr: 6 or 12 mcg 1-2 times daily; up to 48 mcg/day; max: 12 mcg/dose. Inhalation Prophylaxis of exercise-induced bronchospasm Adult: 6 or 12 mcg at least 15 minutes before exercise. Additional dose should only be given after 12 hr; not to be used in patients who are already using it for asthma maintenance. Child: As fumarate: ≥5 yr: 6 or 12 mcg at least 15 minutes before exercise. Additional dose should only be given after 12 hr; not to be used in patients who are already using it for asthma maintenace. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Thyrotoxicosis; severe CV disorders e.g. ischaemic heart disease, tachyarrhythmias or severe heart burn; prolonged QT-interval. DM; pregnancy; lactation; children <5 yr; do not initiate or increase the dose during an exacerbation. May produce paradoxical bronchospasm. |
Adverse Reactions |
Tremor, headache, tiredness, restlessness, dizziness, dry mouth, palpitation, tachycardia, muscle cramps, nausea. |
Overdose Reactions |
Symptoms include angina, hypertension or hypotension, tachycardia, with rates up to 200 beats/minute, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycaemia, insomnia, metabolic acidosis. Treatment is symptomatic and supportive. Cardiac monitoring is recommended. |
Drug Interactions |
Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypokalaemic effect of β-agonists. Increased susceptibility to cardiac arrhythmias in patients treated with digitalis. Concomitant use with quinidine, disopyramide, procainamide, phenothiazines, antihistamines, MAOI or TCAs can prolong the QT-interval and increase the risk of ventricular arrhythmias. L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β2-sympathomimetics. β-adrenergic blockers can inhibit the effect of formoterol. Increased risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons. See Below for More formoterol Drug Interactions |
Mechanism of Actions |
Formoterol relaxes the bronchial smooth muscle by selectively acting on β2-receptors with minimal effect on heart rate. It has a long-acting effect. |
Storage Conditions |
Inhalation: Store below 25°C. Oral: Store below 25°C. |
ATC Classification |
R03AC13 - formoterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases. |
Storage |
Inhalation: Store below 25°C. Oral: Store below 25°C. |
Available As |
|
Formoterol
Post Review about Formoterol Click here to cancel reply.
Formoterol Containing Brands
Formoterol is used in following diseases
Drug - Drug Interactions of Formoterol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.